BusinessA New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in UseBy Nasdaq OMXApr 19, 2018, 1:01 PM UTC
BusinessDaxor Corporation Announces Rise in Kit Sales, New Device Sale, and Filing of Form N-CSR for 2017 (NYSE MKT LLC: DXR)By Nasdaq OMXMar 8, 2018, 5:56 PM UTC
